Form 4: Aptevo Therapeutics COO Reports RSU Conversion and New Grant Vesting

Aptevo Therapeutics' EVP and COO, Jeffrey G. Lamothe, reported the conversion of 5 Restricted Stock Units into common stock and the first vesting of a previously granted 17 RSUs, with future vesting scheduled annually.

Summary

• Jeffrey G. Lamothe, Executive Vice President and Chief Operating Officer of Aptevo Therapeutics Inc. (APVO), filed a Form 4 statement.
• The filing reports the conversion of 5 Restricted Stock Units (RSUs) into common stock on July 17, 2025.
• This conversion represents the first vesting installment of RSUs that were originally granted to Lamothe on July 17, 2024.
• On the grant date of July 17, 2024, Lamothe was granted 17 Restricted Stock Units (post-splits).
• These 17 RSUs are scheduled to vest in three approximately equal annual installments, with the initial vesting occurring on July 17, 2025.
• Following the reported transaction, Lamothe directly beneficially owns 6 shares of common stock.
• After the conversion, Lamothe beneficially owns 12 remaining Restricted Stock Units.
• Restricted Stock Units convert into common stock on a one-for-one basis.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation through equity grants, which aligns management incentives with shareholder interests, reflecting a generally positive but expected corporate governance practice.

Positives

• The grant of 17 Restricted Stock Units (RSUs) to the EVP, COO, Jeffrey G. Lamothe, aligns management's interests with shareholder value through equity incentives.
• The three-year vesting schedule for the RSUs provides a long-term retention mechanism for a key executive, promoting stability and sustained performance.

Negatives

• No specific negative financial or operational information is disclosed in this Form 4 filing, which primarily reports routine insider transactions.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports insider transactions related to executive compensation.

Future Outlook

The remaining 12 Restricted Stock Units granted to Jeffrey G. Lamothe are scheduled to vest in two approximately equal annual installments following the initial vesting on July 17, 2025.

Industry Context

This Form 4 filing details an executive's equity transactions, which is a routine disclosure for publicly traded companies. It does not provide information on broader industry trends or the competitive landscape.

Comparison to Industry Standards

• This Form 4 filing reports an individual executive's stock transactions and does not contain information suitable for comparison to industry-wide financial or operational benchmarks.

Corporate Governance

Related Party Transactions

• Grant of 17 Restricted Stock Units (RSUs) to Jeffrey G. Lamothe, an executive officer (EVP, COO) of Aptevo Therapeutics Inc., as part of his compensation package.
• Conversion of 5 Restricted Stock Units into common stock by Jeffrey G. Lamothe, representing a transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: The grant and vesting of RSUs to a key executive align management's financial interests with shareholder value creation, potentially fostering long-term growth and performance.
• Employees: Reflects standard executive compensation practices within the company, which can influence overall compensation philosophy.

Next Steps

• Future vesting of the remaining 12 Restricted Stock Units in approximately equal annual installments after July 17, 2025.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, APVO, Form 4, SEC filing, insider transaction, Restricted Stock Units, RSU, executive compensation, Jeffrey G. Lamothe, equity incentive